Find information on thousands of medical conditions and prescription drugs.

Telmisartan

Telmisartan is an angiotensin II receptor antagonist (ARB). It is marketed by Boehringer Ingelheim under the tradename Micardis®. Telmisartan is also marketed by Glaxo Group Ltd under the trademark Pritor®. ARBs are prescribed primarily in the treatment of hypertension.

New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

Oxytetracycline

Thiopental sodium

Tranexamic acid

Tranylcypromine

Triamcinolone hexacetonide

Triclabendazole

Trifluoperazine

Tubocurarine chloride

U

V

W

X

Y

Z

Read more at Wikipedia.org

• [List your site here Free!]


		Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.(Observation s) : An article from: Diabetes Care $5.95			Possible beneficial effect of telmisartan on glycemic control in diabetic subjects.(Observations) : An article from: Diabetes Care $5.95


	Other meetings ASCOT results may change hypertension guidelines Full results from the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm (ASCOT-BPLA) ... From Diabetes and Primary Care, 9/22/05

	ARBs vs. ACE inhibitors to prevent nephropathy progression Clinical Question: Are angiotensin receptor blockers (ARBs) as good as angiotensin-converting enzyme (ACE) inhibitors at preventing the progression of nephropathy? Setting: Outpatient (any) Stu From American Family Physician, 3/15/05 by Mark Ebell

	ARB no better than ACE inhibitor for prevention of nephropathy progression CLINICAL QUESTION Are angiotensin receptor blockers as good as angiotensin-converting enzyme inhibitors at preventing the progression of nephropathy? From Journal of Family Practice, 2/1/05

	European Society of Cardiology Congress 2004 & European Association for the Study of Diabetes Annual Meeting: Munich, Germany, 28 August-1 September New data highlight the potential of GLP-1 analogue liraglutide Liraglutide, Novo Nordisk's investigational GLP-1 (glucagon-like peptide 1) analogue, ... From Diabetes and Primary Care, 12/22/04

	Global Rietveld refinement Global optimisation methods of structure determination from powder diffraction data have risen to prominence in a relatively short space of time and ... From Journal of Research of the National Institute of Standards and Technology, 1/1/04 by Kenneth Shankland

	Irbesartan-associated persistent edema of the eyelids, face, and neck - Case Reports Abstract Irbesartan, an angiotensin II receptor antagonist (AIIRA), is an antihypertensive agent that inhibits the activity of angiotensin II by selectively ... From Journal of Drugs in Dermatology, 12/1/02 by Philip R. Cohen

	Correction - To: "Spironolactone in Left-Sided Heart Failure: How Does It Fit In?" in October 15, 2001 issue, page 1393 The article "Spironolactone in Left-Sided Heart Failure: How Does It Fit In?" (October 15, 2001, page 1393) contained an error in Table 4 on page 1397. From American Family Physician, 6/1/02

	Combination HT Therapy - Hypertension The combination of an angiotensin receptor blocker plus hydrochiorothiazide is a more cost-effective treatment for hypertension than an angiotensin receptor blocker alone, Daniel E. Hilleman, Pharm From OB/GYN News, 1/15/02 by Sally Koch Kubetin

Home

Contact

Resources

ebay